Details of Drug

Details of Drug

 Drug General Information (ID: D1376)
  Drug Name
Raloxifene
  Drug Type Small molecule
  Drug Synonymous
Raloxifene (extended-release, CDT)
    Click to Show/Hide
  Disease Class FB83: Low bone mass disorder
  Therapeutic Class Hormones/Antineoplastics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C28H27NO4S
  InChI 1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
  InChIKey GZUITABIAKMVPG-UHFFFAOYSA-N
  Canonical SMILES C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
  External Link
Pubchem ID 5035
CAS Number 84449-90-1
CHEBI ID 8772
TTD ID D01XBA
INTEDE ID DR1388
VARIDT ID DR01347

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM003  Affected organization distribution
AM006  Pharmacodynamic additive effects
BM003  Complex formation
BM013  Competitive binding of plasma proteins
BM047  Additive thrombogenic effects
BM109  Increased risk of other adverse reactions (Unspecific)
  Relation Graph
 Full list of drugs interacting with Raloxifene
      Affected gastrointestinal absorption
   Complex formation Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0382
 
Colestipol
 
C11H28ClN5O
 
62816 
Moderate    Inter Info   
[14]
D0329
 
Cholestyramine
 
C27H47ClN2
 
137699107 
Moderate    Inter Info   
[14]
      Affected organization distribution
   Competitive binding of plasma proteins Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0927
 
Lidocaine
 
C14H22N2O
 
3676 
Minor    Inter Info   
[14]
D0473
 
Diazepam
 
C16H13ClN2O
 
3016 
Minor    Inter Info   
[14]
D0474
 
Diazoxide
 
C8H7ClN2O2S
 
3019 
Minor    Inter Info   
[14]
      Pharmacodynamic additive effects
   Additive thrombogenic effects Drug Num:  7
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0902
 
Lenalidomide
 
C13H13N3O3
 
216326 
Major    Inter Info   
[1], [3], [4]
D0261
 
Carfilzomib
 
C40H57N5O7
 
11556711 
Major    Inter Info   
[5], [6], [1]
D1312
 
Pomalidomide
 
C13H11N3O4
 
134780 
Major    Inter Info   
[7], [8], [9]
D1569
 
Thalidomide
 
C13H10N2O4
 
5426 
Major    Inter Info   
[1], [7], [10]
D1619
 
Tranexamic acid
 
C8H15NO2
 
5526 
Major    Inter Info   
[11], [12], [13]
D0385
 
Conestat alfa
 
NA
 
NA
Moderate    Inter Info   
[15], [16], [17], [18]
D0762
 
Human C1-esterase inhibitor
 
NA
 
NA
Moderate    Inter Info   
[15], [17], [18]
   Increased risk of other adverse reactions (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0178
 
Bexarotene
 
C24H28O2
 
82146 
Major    Inter Info   
[1], [2]
References
1 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2 Product Information. Targretin (bexarotene) Ligand Pharmaceuticals, San Diego, CA.
3 Product Information. Revlimid (lenalidomide). Celgene Corporation, Summit, NJ.
4 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
5 Cerner Multum, Inc. "Australian Product Information.".
6 Product Information. Kyprolis (carfilzomib). Onyx Pharmaceuticals Inc, South San Francisco, CA.
7 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
8 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
9 Therapeutic Research Faculty "Natural Medicines Comprehensive Database."
10 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
11 Product Information. Cyklokapron (tranexamic acid). Pharmacia and Upjohn, Kalamazoo, MI.
12 van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR "The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study." BMJ 339 (2009): b2921.[PMID: 19679614]
13 Gomes MP, Deitcher SR "Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review." Arch Intern Med 164 (2004): 1965-76.[PMID: 15477430]
14 Product Information. Evista (raloxifene). Lilly, Eli and Company, Indianapolis, IN.
15 Product Information. Berinert (complement C1 esterase inhibitor). CSL Behring, King of Prussia, PA.
16 Product Information. Cinryze (complement C1 esterase inhibitor). ViroPharma Incorporated, Exton, PA.
17 Product Information. Ruconest (conestat alfa). Valeant Pharmaceuticals, Costa Mesa, CA.
18 Gandhi PK, Gentry WM, Bottorff MB "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy 32 (2012): 902-9. [PMID: 23033229]